- Oops!Something went wrong.Please try again later.
ManpowerGroup Inc. MAN is currently benefiting from strong pricing and cost-control initiatives.
The company recently reported first-quarter 2021 adjusted earnings of $1.11 per share that beat the Zacks Consensus Estimate by 68.2% and increased 35.4% year over year. Revenues of $4.92 billion surpassed the consensus mark by 5.6% and inched up 7% year over year.
ManpowerGroup’s shares have gained a massive 67.3% over the past year, significantly outperforming the Zacks S&P 500 composite’s 41.5% rally.
The company is trying to strengthen its top line through strong pricing and cost control. Its Managed Service Provider business is resilient to the coronavirus crisis and continues to witness decent growth as it assists more clients in building customized workforce solutions.
Commitment to shareholder returns makes ManpowerGroup a reliable investment to compound wealth over long term. The company returned $264.7 million, $203 million and $500.7 million through share repurchases and made dividend payments of $129.1 million, $129.3 million and $127.3 million, respectively, in 2020, 2019 and 2018. These initiatives not only instill investors' confidence but also positively impact earnings per share.
ManpowerGroup's cash and cash equivalent balance of $1.52 billion at the end of the first quarter was well above the total debt level of $1.08 billion, underscoring that the company has enough cash to meet its debt burden. A strong cash position enables the company to pursue strategic acquisitions, invest in growth initiatives and return cash through regular quarterly dividend payment and share repurchases.
Zacks Rank and Stocks to Consider
ManpowerGroup currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some other top-ranked stocks in the broader Zacks Business Services sector are Genpact G, Equifax EFX and TransUnion TRU, each carrying a Zacks Rank #2.
The long-term expected earnings per share (three to five years) growth rate for Genpact, Equifax and TransUnion is 12.8%, 14% and 20.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Equifax, Inc. (EFX) : Free Stock Analysis Report
ManpowerGroup Inc. (MAN) : Free Stock Analysis Report
Genpact Limited (G) : Free Stock Analysis Report
TransUnion (TRU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research